CIAN
VRTX icon

Capstone Investment Advisors (Netherlands)’s Vertex Pharmaceuticals VRTX Stock Holding History

Capstone Investment Advisors (Netherlands)’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-544
Closed -$40K – 178
2016
Q4 		$40K Buy
+544
New +$44.3K 0.07% 164

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Capstone Investment Advisors (Netherlands)'s VRTX Position: Q1 2017 in Review

Capstone Investment Advisors (Netherlands) sold out of Vertex Pharmaceuticals (VRTX) in Q1 2017, closing a stake of 544 shares — an estimated $40K sold.

Capstone Investment Advisors (Netherlands) first reported a position in VRTX in Q4 2016 and held it in 1 quarter. The position peaked at $40K in Q4 2016. 522 funds tracked by Wall St. Rank hold VRTX as of Q1 2017.

  • Capstone Investment Advisors (Netherlands) reported no remaining Vertex Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Capstone Investment Advisors (Netherlands) sold 544 Vertex Pharmaceuticals shares in Q1 2017, an estimated $40K.
  • Capstone Investment Advisors (Netherlands) first reported a position in Vertex Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • Capstone Investment Advisors (Netherlands)'s Vertex Pharmaceuticals position peaked at $40K in Q4 2016.
  • 522 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2017.

Based on Capstone Investment Advisors (Netherlands)'s 13F filing for Q1 2017, filed 15 May 2017.